3,6-disubstituted xanthylium salts and use thereof in treatment of tauopathies
View Patent ↗This invention pertains generally to processes, uses, methods and materials utilizing particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
1. A method of treatment of a tauopathy condition or a disease of tau protein aggregation in a patient in need thereof comprising administering to the patient a compound of formula (I):
wherein:
X − is a counter ion;
—R 5 is independently —H, or saturated C 1-6 alkyl, which is unsubstituted or substituted with one or more substituents —R 5A , or phenyl, which is unsubstituted or substituted with one or more substituents —R 5A ;
each —R 5A is independently selected from —F, —Cl, —Br, —I, —OH, —OR 6 , —SH, —SR 6 , —CN, —NO 2 , —NH 2 , —NHR 6 , —NR 6 2 , —NHC(═O)R 6 , —NR 6 C(═O)R 6 , —C(═O)OR 6 , —OC(═O)R 6 , —C(═O)NH 2 , —C(═O)NHR 6 , and —C(═O)NR 6 2 , —C(═O)R 6 , —C(═O)OH, —S(═O)R 6 , —S(═O) 2 R 6 , and —S(═O) 2 OH;
each —R 6 is independently saturated aliphatic C 1-4 alkyl, phenyl, or benzyl;
—R 13a , —R 13b , —R 14a , —R 14b , —R 15a , —R 15b , —R 16a , and —R 16b are each independently selected from H and saturated aliphatic C 1-4 alkyl.
2. A method according to claim 1 , wherein X − is selected from the group consisting of: NO 3 − , ClO 4 − , F − , Cl − , Br − , I − , ZnCl 3 − , FeCl 4 − and PF 6 − .
3. A method according to claim 1 , wherein —R 5 is independently —H, or saturated aliphatic C 1-6 alkyl, which is unsubstituted or substituted with one or more substituents —R 5A .
4. A method according to claim 1 , wherein —R 5 is saturated aliphatic C 1-4 alkyl, which is unsubstituted or substituted with one or more substituents —R 5A .
5. A method according to claim 4 , wherein each —R 5A is independently selected from —F, —Cl, —Br, or —I.
6. A method according to claim 4 , wherein —R 5 is —CF 3 .
7. A method according to claim 1 , wherein —R 5 is phenyl, which is substituted with one or more substituents —R 5A .
8. A method according to claim 7 , wherein each —R 5A is independently selected from NH 2 and NO 2 .
9. A method according to claim 4 , wherein —R 5 is -Et.
10. A method according to claim 1 , wherein the compound is a compound of formula (Ic):
wherein X and R 5 are as defined for the compounds of formula (I).
11. A method according to claim 1 , wherein the compound is selected from the group consisting of:
Com-
pound
Structure and Name
A
B
C
D
AE
12. A method according to claim 1 , wherein the compound is provided in the form of a dosage unit comprising the compound in an amount of from 20 to 300 mg and a pharmaceutically acceptable carrier, diluent, or excipient.
13. A method according to claim 1 , wherein the treatment comprises administration of the compound according to one of the following dosage regimes: about 50 or about 75 mg, 3 or 4 times daily; or about 100 or about 125 mg, 2 times daily.
14. A method according to claim 1 , wherein the treatment comprises oral administration of the compound.
15. A method according to claim 1 , wherein the treatment further comprises treatment with at least one of the following: a cholinesterase inhibitor; Donepezil, Rivastigmine, or Galantamine; an NMDA receptor antagonist; Memantine; a muscarinic receptor agonist; an inhibitor of amyloid precursor protein processing to beta-amyloid.
16. A method of reversing or inhibiting the aggregation of tau protein comprising contacting the aggregate or protein with a compound as defined in claim 1 .
17. A method of regulating the aggregation of a tau protein in the brain of a mammal, which aggregation is associated with a disease of tau protein aggregation, comprising the step of administering to said mammal a therapeutically effective amount of a compound as defined in claim 1 .
18. A method of inhibiting production of protein aggregates in the brain of a mammal, comprising the step of administering to said mammal a therapeutically effective amount of a compound as defined in claim 1 .
19. A method of treatment of a tauopathy condition in a patient comprising administering to said patient a compound as defined in claim 1 .
20. A method of treatment of a disease of tau protein aggregation in a patient comprising administering to said patient a compound as defined in claim 1 .
21. A method of treatment of Alzheimer's disease (AD), Pick's disease, Progressive Supranuclear Palsy (PSP), fronto-temporal dementia (FTD), parkinsonism linked to chromosome 17 (FTDP-17), disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido-nigro-luysian degeneration (PNLD), cortico-basal degeneration (CBD), Dementia with Argyrophilic grains (AgD), Dementia pugilistica (DP), Down's Syndrome (DS), Dementia with Lewy bodies (DLB) Subacute sclerosing panencephalitis (SSPE), MCI, Neumann Pick disease, type C(NPC), Sanfilippo syndrome type B, mucopolysaccharidosis III B (MPS III B), myotonic dystrophies (DM), DM1 or DM2, or chronic traumatic encephalopathy (CTE) in a patient, comprising administering to said patient a compound as defined in claim 1 .
22. A method of treatment of Alzheimer's disease (AD) in a patient, comprising administering to said patient a compound as defined in claim 1 .